Cocrystal Pharma, Inc.
Datakwaliteit: 83%
COCP
Nasdaq
Manufacturing
Chemicals
€ 1,46
▲
€ 0,02
(1,39%)
Marktkapitalisatie: 20,13 M
Prijs
€ 1,46
Marktkapitalisatie
20,13 M
Dagbereik
€ 1,36 — € 1,52
52-Weeksbereik
€ 0,86 — € 2,67
Volume
498.858
Openen € 1,40
50D / 200D Gem.
€ 1,03
41,17% above
50D / 200D Gem.
€ 1,23
18,86% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -8,20 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-135,84%
Onder sectorgemiddelde (-53,47%)
ROIC-91,35%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio5,78
Interest Coverage-67,31
Waardering
PE (TTM)
-2,28
Onder sectorgemiddelde (-1,47)
P/B Ratio2,62
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,3 | -1,5 |
| P/B | 2,6 | 1,6 |
| ROE % | -135,8 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -8,83 M |
| ROE | -135,84% | ROA | -93,20% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -8,20 M |
| ROIC | -91,35% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5,78 |
| Interest Coverage | -67,31 | Asset Turnover | N/A |
| Working Capital | 7,26 M | Tangible Book Value | 7,67 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,28 | Forward P/E | N/A |
| P/B Ratio | 2,62 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -40,76% | ||
| Market Cap | 20,13 M | Enterprise Value | 20,13 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,78 | Revenue / Share | N/A |
| FCF / Share | -0,60 | OCF / Share | -0,59 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 92,90% |
| SBC-Adj. FCF | -8,67 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 2,01 M |
| Net Income | -8,83 M | -17,50 M | -17,98 M | -38,84 M | -14,19 M |
| EPS (Diluted) | -0,78 | -1,72 | -1,87 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9,02 M | -17,88 M | -18,56 M | -38,83 M | -14,22 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5,06 M | 12,54 M | 15,17 M | 12,39 M | 8,79 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 72.000,0 | 126.000,0 | 189.000,0 | 185.000,0 | 190.000,0 |
| Interest Expense | -134.000,0 | -537.000,0 | -640.000,0 | 2.000,0 | 4.000,0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 9,71 M | 13,46 M | 31,26 M | 40,84 M | 79,39 M |
| Total Liabilities | 3,38 M | 3,93 M | 4,88 M | 1,27 M | 1,84 M |
| Shareholders' Equity | 6,33 M | 9,52 M | 26,38 M | 39,57 M | 77,55 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 7,03 M | 9,86 M | 26,35 M | 37,22 M | 58,71 M |
| Current Assets | 8,13 M | 11,58 M | 29,09 M | 40,18 M | 59,32 M |
| Current Liabilities | 2,21 M | 2,43 M | 3,26 M | 1,22 M | 1,55 M |
{"event":"ticker_viewed","properties":{"ticker":"COCP","listing_kind":"stock","pathname":"/stocks/cocp","exchange":"Nasdaq","country":"US"}}